HDV Insulin - Diasome Pharmaceuticals
Alternative Names: HDV Humalog; HDV Insulin Lispro; HDV-I; HDV-Insulin; HDV-L; Hepatic Directed Vesicle Insulin LisproLatest Information Update: 14 Feb 2024
At a glance
- Originator Diasome Pharmaceuticals
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 23 Jan 2024 Diasome Pharmaceuticals initiates a phase IIb OPTI-2 trial for Type-1 diabetes mellitus (Treatment-experienced) in USA (Parenteral, Injection) (NCT06238778)
- 07 Dec 2023 HDV is still in phase II trials for Type 2 diabetes mellitus in USA
- 07 Dec 2023 HDV is still in phase II trials for Type 1 diabetes mellitus in USA